Tomasz Huzarski
Overview
Explore the profile of Tomasz Huzarski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
197
Citations
6949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szwiec M, Tomiczek-Szwiec J, Marciniak W, Derkacz R, Huzarski T, Cybulski C, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075686
Purpose: Among patients treated with neoadjuvant chemotherapy (NAC), a high survival rate is observed for those who experience a pathological complete response (pCR). Various tumor factors are predictive of a...
2.
Feszak S, Feszak I, Kluzniak W, Wokolorczyk D, Stempa K, Gliniewicz K, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002208
: Ductal carcinoma in situ (DCIS) is the most common non-invasive form of breast cancer. It is not clear to what extent DCIS is a part of the hereditary breast/ovarian...
3.
Katona B, Lubinski J, Pal T, Huzarski T, Foulkes W, Moller P, et al.
Cancer
. 2024 Nov;
131(1):e35666.
PMID: 39611336
Background: The lifetime risk of pancreatic cancer in women with a germline mutation in BRCA1 and BRCA2 is not well established. In an international prospective cohort of female carriers of...
4.
Matuszczak M, Kiljanczyk A, Marciniak W, Derkacz R, Stempa K, Baszuk P, et al.
Hered Cancer Clin Pract
. 2024 Sep;
22(1):19.
PMID: 39300540
Objective: To investigate whether Molybdenum blood level is a marker of cancer risk on BRCA1 carriers. Methods: A prospective cohort study was conducted among 989 initially unaffected women with a...
5.
Kotsopoulos J, Lubinski J, Huzarski T, Bychkovsky B, Moller P, Kim R, et al.
Gynecol Oncol
. 2024 Aug;
189:148-155.
PMID: 39173195
Objective: Whether or not women who harbor a germline pathogenic variant ('mutation') in the BRCA1 or BRCA2 genes are at elevated risk of developing endometrial cancer is yet to be...
6.
Pietrzak S, Marciniak W, Derkacz R, Matuszczak M, Kiljanczyk A, Baszuk P, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123346
Prostate cancer is the most common cancer diagnosed in men and the second leading cause of death in male cancer patients. The WHO suggests that cobalt is involved in the...
7.
Matuszczak M, Kiljanczyk A, Marciniak W, Derkacz R, Stempa K, Baszuk P, et al.
Antioxidants (Basel)
. 2024 Jul;
13(7).
PMID: 39061909
Pathogenic mutations in BRCA1 (BReast CAncer gene 1) confer high risks of both breast (up to 70%) and ovarian (up to 40%) cancers. Zinc (Zn) and copper (Cu) are essential...
8.
Narod S, Gronwald J, Karlan B, Moller P, Huzarski T, Tung N, et al.
J Natl Cancer Inst
. 2024 Jun;
116(11):1753-1760.
PMID: 38937272
Background: To estimate the incidence of primary peritoneal cancer after preventive bilateral oophorectomy in women with a BRCA1 or BRCA2 mutation. Methods: A total of 6310 women with a BRCA1...
9.
Kiljanczyk A, Matuszczak M, Marciniak W, Derkacz R, Stempa K, Baszuk P, et al.
Nutrients
. 2024 Jun;
16(11).
PMID: 38892720
Breast cancer and ovarian cancer pose a significant risk for BRCA1 carriers, with limited risk-reduction strategies. While improved screening helps in the early detection of breast cancer, preventive measures remain...
10.
Matuszczak M, Kiljanczyk A, Marciniak W, Derkacz R, Stempa K, Baszuk P, et al.
Antioxidants (Basel)
. 2024 May;
13(5).
PMID: 38790714
BRCA1 mutations predispose women to breast and ovarian cancer. The anticancer effect of zinc is typically linked to its antioxidant abilities and protecting cells against oxidative stress. Zinc regulates key...